Cargando…

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain

Sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like-peptide-1 receptor (GLP-1-R) agonists are novel therapeutic agents used for the management of type 2 diabetes mellitus (T2DM). Recently, large-scale randomized clinical trials have been conducted to assess the cardiovascular safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rolek, Bartosz, Haber, Mateusz, Gajewska, Magdalena, Rogula, Sylwester, Pietrasik, Arkadiusz, Gąsecka, Aleksandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455499/ https://www.ncbi.nlm.nih.gov/pubmed/37623335 http://dx.doi.org/10.3390/jcdd10080322

Ejemplares similares

Coronary slow flow and microvascular spasm as an underrecognized cause of chest pain
por: Figura, Emilia, et al.
Publicado: (2023)

Occlusive myocardial infarction – emerging paradigm of acute coronary syndromes
por: Rolek, Bartosz, et al.
Publicado: (2023)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Haemodynamic monitoring in acute heart failure – what you need to know
por: Jasińska-Gniadzik, Karolina, et al.
Publicado: (2022)

LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
por: Winiarska, Agata, et al.
Publicado: (2021)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Challenging two-staged percutaneous coronary intervention in multivessel coronary artery disease with a high SYNTAX score: feasible, yet complicated
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

Iatrogenic subclavian artery puncture repair with Angio-Seal deployment and balloon occlusion
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

The Effect of a Vegan Diet on the Cardiovascular System
por: Koutentakis, Michail, et al.
Publicado: (2023)

Hybrid treatment of massive pulmonary embolism by catheter-directed and surgical embolectomy
por: Pietrasik, Arkadiusz, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
por: Dadwani, Rahul S., et al.
Publicado: (2023)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding?
por: Rogula, Sylwester P., et al.
Publicado: (2020)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Safety and Efficacy of DOACs in Patients with Advanced and End-Stage Renal Disease
por: Rogula, Sylwester, et al.
Publicado: (2022)

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
por: Goncalves, Edison, et al.
Publicado: (2018)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
por: King, Nicholas E., et al.
Publicado: (2022)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Percutaneous removal of a catheter fragment from the right atrium
por: Pietrasik, Arkadiusz, et al.
Publicado: (2021)

Mechanical circulatory support for high-risk percutaneous coronary interventions and cardiogenic shock: Rationale and design of the multicenter, investigator-initiated IMPELLA-PL registry
por: Pietrasik, Arkadiusz, et al.
Publicado: (2022)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
por: Gonzalez, Jimmy, et al.
Publicado: (2023)

Catheter-directed therapy to treat intermediate- and high-risk pulmonary embolism: Personal experience and review of the literature
por: Pietrasik, Arkadiusz, et al.
Publicado: (2022)

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
por: Gurgle, Holly E, et al.
Publicado: (2016)

Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
por: Natali, Andrea, et al.
Publicado: (2021)

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
por: Baviera, Marta, et al.
Publicado: (2022)

Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
por: Dzaye, Omar, et al.
Publicado: (2022)

PSUN172 Prescribing SGLT-2 Inhibitors and GLP-1 Agonists in Primary Care: Improving Rates of Guideline-Concordant Practice
por: Schuetz, Samantha, et al.
Publicado: (2022)

Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
por: Muller, Dion R. P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a933bvjnu1isqkcbvch5bgpg23